Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells $357,372.56 in Stock

Posted by Ethan Ryder on Apr 3rd, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 29,102 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $12.28, for a total transaction of $357,372.56. Following the completion of the sale, the insider now directly owns 3,141,682 shares in the company, valued at $38,579,854.96. This represents a 0.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.58, for a total transaction of $611,677.34.
On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.01, for a total transaction of $428,315.22.
On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.62, for a total value of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total value of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.95, for a total transaction of $599,668.65.
On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.03, for a total transaction of $25,899.38.
On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.27, for a total transaction of $216,090.61.
On Wednesday, January 29th, Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.12, for a total transaction of $164,836.88.

Abrdn Life Sciences Investors Stock Performance

HQL stock traded down $0.12 during midday trading on Thursday, hitting $12.19. The company’s stock had a trading volume of 99,299 shares, compared to its average volume of 99,230. The firm’s 50-day moving average is $13.47 and its 200-day moving average is $14.04. Abrdn Life Sciences Investors has a 12 month low of $12.14 and a 12 month high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Friday, February 21st were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Friday, February 21st. This represents a $1.88 annualized dividend and a dividend yield of 15.42%.

Institutional Investors Weigh In On Abrdn Life Sciences Investors

Large investors have recently bought and sold shares of the business. Absolute Investment Advisers LLC purchased a new stake in shares of Abrdn Life Sciences Investors during the 4th quarter valued at about $5,242,000. Raymond James Financial Inc. bought a new stake in Abrdn Life Sciences Investors in the 4th quarter worth approximately $3,129,000. LPL Financial LLC raised its stake in Abrdn Life Sciences Investors by 82.0% during the 4th quarter. LPL Financial LLC now owns 287,095 shares of the company’s stock valued at $3,767,000 after buying an additional 129,313 shares during the last quarter. Wolverine Asset Management LLC bought a new position in shares of Abrdn Life Sciences Investors during the 4th quarter valued at $1,594,000. Finally, Jane Street Group LLC purchased a new position in shares of Abrdn Life Sciences Investors in the 4th quarter worth $290,000. 32.21% of the stock is currently owned by institutional investors.

About Abrdn Life Sciences Investors

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.